Investor Presentation
11
Investor presentation First six months of 2022
Once-weekly insulin Icodec demonstrated superior HbA1c
reduction in people with type 2 diabetes in ONWARDS 1-3 trials
ONWARDS
Duration
1
2
3
5
Basal initiation
52 weeks
Basal initiation
Basal switch
Basal initiation
4
Basal/Bolus
52 weeks²
26 weeks
26 weeks
26 weeks
(Full trial: 78 weeks)
984
526
588
582
Baseline
Change in
HbA1c (%)
8.5%
8.1%
8.5%
8.3%
N/A
Participants
1,085
6
Basal/Bolus
26 weeks²
(Full trial: 52 weeks)
582
7.6%
-0.47% -0.51%
Hypo-
glycaemia
event rates¹
-0.71%
-0.93%*
-1.35%
-1.55%*
0.30
0.16
0.73 0.27
-1.16% -1.18%
-1.36%
-1.57%*
0.31 0.15
5.64 5.62
In people with type 2 diabetes: No statistical difference in estimated hypoglycaemia events
Once-weekly insulin icodec
Once-daily insulin glargine U100
Once-daily insulin degludec
19.93
10.37*
Novo NordiskⓇ
In people with type 1
diabetes
* Statistically significant in terms of superiority. 'Severe or clinically significant hypoglycaemia events (blood glucose <3 mmol/L) per patient year 2 Duration refers to trial main phase. T1D: Type 1 diabetes; T2D: Type 2 diabetes
ONWARDS 1: QW insulin icodec vs QD insulin glargine U100 both with non-insulin anti-diabetic treatment in insulin-naïve people with T2D; ONWARDS 2: QW insulin icodec vs QD insulin degludec in people with T2D switching from a QD insulin; ONWARDS 3: QW
insulin icodec vs QD insulin degludec in insulin-naïve people with T2D; ONWARDS 4: QW insulin icodec vs QD insulin degludec both with mealtime insulin in people with T2D treated with basal and bolus insulin; ONWARDS 5: QW insulin icodec vs QD basal insulin
with an app providing dosing recommendation in insulin-naïve people with T2D; ONWARDS 6: QW insulin icodec vs QD insulin degludec both with mealtime insulin in people with T1DView entire presentation